Alterity Therapeutics (NASDAQ:ATHE) Director Peter Ashley Marks Acquires 47,620 Shares

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Director Peter Ashley Marks bought 47,620 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was acquired at an average cost of $0.50 per share, with a total value of $23,810.00. Following the transaction, the director owned 191,340 shares of the company’s stock, valued at $95,670. This represents a 33.13% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Alterity Therapeutics Stock Performance

Alterity Therapeutics stock opened at $4.51 on Wednesday. The firm has a 50-day moving average of $4.78 and a 200-day moving average of $4.31. Alterity Therapeutics Limited – Sponsored ADR has a one year low of $2.66 and a one year high of $5.89.

Alterity Therapeutics (NASDAQ:ATHE) last released its earnings results on Thursday, July 30th. The company reported ($0.28) earnings per share (EPS) for the quarter. The company had revenue of $0.31 million during the quarter. Analysts forecast that Alterity Therapeutics Limited – Sponsored ADR will post -0.12 EPS for the current year.

Wall Street Analyst Weigh In

ATHE has been the subject of several recent analyst reports. Craig Hallum set a $2.00 price objective on Alterity Therapeutics in a report on Tuesday, August 11th. JonesTrading started coverage on shares of Alterity Therapeutics in a research report on Tuesday, June 30th. They set a “buy” rating and a $16.00 price target on the stock. LADENBURG THALM/SH SH started coverage on shares of Alterity Therapeutics in a research note on Tuesday, June 16th. They issued a “buy” rating and a $10.00 price target for the company. Zacks Research raised shares of Alterity Therapeutics to a “hold” rating in a research report on Wednesday, June 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alterity Therapeutics stock. Citadel Advisors LLC bought a new position in shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned about 0.25% of Alterity Therapeutics at the end of the most recent quarter. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.